A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Clinical trial NCT05765812 · RECRUITING

Trial details

NCT number: NCT05765812
Sponsor: Debiopharm International SA
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Astrocytoma, Grade III

Start date: 2023-05-15
Primary completion: 2028-09-01
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.